• Aucun résultat trouvé

Document Number: 1233402 Version: 3

N/A
N/A
Protected

Academic year: 2022

Partager "Document Number: 1233402 Version: 3"

Copied!
1
0
0

Texte intégral

(1)AbbVie Files Form 8-K NORTH CHICAGO, ILLINOIS, U.S.A., May 6, 2016 – AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has filed a Periodic Report on Form 8-K/A with the U.S. Securities and Exchange Commission (“SEC”) amending the April 25, 2016 announcement regarding the Agreement and Plan of Merger (the “Merger Agreement”) with Stemcentrx, Inc., a Delaware corporation (“Stemcentrx”), Sirius Sonoma Corporation, a Delaware corporation and wholly owned subsidiary of AbbVie, Sirius Sonoma LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie and, for certain purposes described in the Merger Agreement, Fertile Valley LLC, a Delaware limited liability company, pursuant to which Stemcentrx will be acquired by AbbVie. AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after AbbVie electronically files these documents with, or furnishes them to, the SEC. These documents are posted on AbbVie’s website at www.abbvieinvestor.com. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC’s home page at http://www.sec.gov. Copies of the above referenced information will also be made available, free of charge, upon written request to AbbVie Inc., Investors Relations, 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A.. Document Number: 1233402. Version: 3. WorldReginfo - 27ce8a91-68b2-4e18-8e45-7faa3cf955e1. Contact: AbbVie Inc., 1-847-938-8745.

(2)

Références

Documents relatifs

In Australia – Apples, the Appellate Body confirmed that a violation of Article 5.6 requires proof by the complainant that ‘a proposed alternative measure to the measure at issue:

On May 24, 2016, the administrator of the AbbVie Savings Plan the “Savings Plan” and the AbbVie Puerto Rico Savings Plan the “PR Savings Plan” collectively, the “Plans,” and

or global capital markets, credit markets or economies generally that could significantly impact AbbVie’s ability to implement, or realize the benefits of, the accelerated

The Maximum Number for a particular annual meeting shall be reduced by: i such Nominees nominated by a Nominating Stockholder pursuant to this Section 2.13 for such annual meeting

Notwithstanding any other provision of the Plan, if a participant incurs a termination of employment with AbbVie and its subsidiaries for any reason within two 2 years following

The u nacceptab ili ty of (Il b) could presumab ly fo ll ow from a strict interpretation of the princi ples of derivat ional economy. 1 would like to maintain, however,

It is suggested that the principle of effective interpretation calls for the harmonious interpretation and application of both rights and obligations. In US-Gasoline, the

I wish to confirm the understanding which has been reached between the United Nations and the Imperial Ethiopian Government regarding the interpretation to be placed on Article V